Project: Bench, Bedside, Business, and Beyond: innovative solutions for AMR diagnostics

Acronym	B2B2B AMRDx (Reference Number: JPIAMR_NC_2022-008)
Project Topic	As antimicrobial resistance (AMR) becomes more widespread, efforts to extend the usability of current antimicrobial agents by developing and applying diagnostics to identify the appropriate narrow-spectrum antimicrobial for each infection take centre stage. However, diagnostic developers currently suffer from late-stage attrition, creating a “valley of death” that prevents diagnostic tools from reaching patients. The B2B2B AMRDx network is a cross-disciplinary, geographically diverse and gender-balanced group of partners from universities (bench), hospitals (bedside), for-profits (business), governments and nonprofits (beyond), with expertise in all One Health settings: human, animal, and environmental AMR. Improved communications between stakeholders in multiple sectors, an objective of the WHO’s Oslo Medicines Initiative, benefits the development of rapid, reliable AMR diagnostics. We focus on 3 objectives to address the challenges faced by AMR diagnostics developers. Objective 1 expands an open, self-curated, comprehensive online AMR Diagnostics Developer Directory (ADDD) to facilitate exchange of ideas and create synergies in the field. Objective 2 further develops the JPIAMR Seq4AMR Virtual Benchmarking Platform (VBP) for genotype-to-phenotype microbial benchmarking studies that will include gold standard whole genome sequences, phenotypes, and metadata, as well as accompanying microbial isolates. Objective 3 defines policy Pathways to AMR-specific Incentives for Developing Diagnostics (PAIDD), maximising public health benefits from the use of AMR diagnostics.
Website	visit project website
Network	JPIAMR-ACTION
Call	3rd JPIAMR-ACTION Joint Call 2022

Project partner

Number	Name	Role	Country
1	Imperial College London	Coordinator	United Kingdom
2	Norwegian Institute of Public Health	Observer	Norway
3	Norwegian Institute of Public Health	Observer	Norway
4	Global Access Diagnostics	Observer	United Kingdom
5	Ss. Cyril and Methodius University of Skopje	Observer	macedonia, republic of
6	University of Edinburgh	Observer	United Kingdom
7	Univ. Med. Greifswald	Observer	Germany
8	Canadian Food Inspection Agency	Observer	Canada
9	University of Bern	Observer	Switzerland
10	UK Health Security Agency	Observer	United Kingdom
11	Vita-Salute San Raffaele	Observer	Italy
12	Canadian Food Inspection Agency	Observer	Canada
13	Universidad Nacional Autónoma de México, Cuernavaca	Observer	Mexico
14	Vita-Salute San Raffaele	Observer	Italy
15	Biomedicine Institute of Valencia, Spanish National Research Council	Observer	Spain
16	Canadian Food Inspection Agency	Observer	Canada
17	Institute of Phthisiopneumology	Observer	Moldova
18	University of Copenhagen	Observer	Denmark
19	CHU Lyon	Observer	France
20	University of Liverpool	Observer	United Kingdom
21	BIOASTER	Observer	France
22	CHU Lyon	Observer	France
23	University of Cairo	Observer	Egypt
24	Barcelona Institute for Microelectronics, Consejo Superior Investigaciones Científicas	Observer	Spain
25	Foundation for Innovative New Diagnostics	Observer	Switzerland
26	San Pier Damiano Hospital	Observer	Italy
27	University of Exeter	Observer	United Kingdom
28	Centre Hospitalier Universitaire Vaudois	Observer	Switzerland
29	Biological Research Centre, Lithuanian University of Health Sciences	Observer	Lithuania
30	Microplate Dx	Observer	United Kingdom
31	Erasmus University Medical Centre	Observer	Netherlands
32	EMPE Diagnostics	Observer	Sweden
33	Infectious diseases, Roche Dia	Observer	Switzerland
34	Imperial College	Observer	United Kingdom
35	Lithuanian University of Health Sciences	Observer	Lithuania
36	Jagiellonian University	Observer	Poland
37	Nostics	Observer	Netherlands
38	Imperial College London	Observer	United Kingdom
39	Centre for Disease Dynamics, Economics & Policy	Observer	United States
40	BIOASTER	Observer	France
41	Roche	Observer	Switzerland
42	Consejo Superior Investigaciones Científicas	Observer	Spain
43	Fondation Mérieux	Observer	France
44	McMaster University	Observer	Canada
45	Fachhochschule Nordwestschweiz	Observer	Switzerland
46	Vita-Salute San Raffaele	Observer	Italy
47	Hahn-Schickard	Observer	Germany
48	TreatSystems	Observer	Denmark
49	University of Bern	Observer	Switzerland
50	University of Copenhagen	Observer	Denmark
51	Sinai Health	Observer	Canada
52	Fondation Mérieux	Observer	France
53	Nostics	Observer	Netherlands
54	Imperial College	Observer	United Kingdom
55	CHU Lyon	Observer	France
56	Vita-Salute San Raffaele	Observer	Italy
57	Tallinn University of Technology	Observer	Estonia
58	Erasmus University Medical Centre	Observer	Netherlands
59	Resistell	Observer	Switzerland
60	Foundation for Innovative New Diagnostics	Observer	Switzerland
61	UK Health Security Agency	Observer	United Kingdom
62	University of Durban	Observer	South Africa
63	Swedish University of Agricultural Sciences	Observer	Sweden
64	Foundation for Innovative New Diagnostics	Observer	Switzerland
65	AMR Insights BV	Observer	Netherlands
66	CHU Lyon	Observer	France
67	The Belgian Institute for Health	Observer	Belgium
68	University of Barcelona	Observer	Spain
69	Maynooth University	Observer	Ireland